Diatech Pharmacogenetics updates its kit for the analysis of KRAS and NRAS on the basis of the Amgen-AIFA information note

//Diatech Pharmacogenetics updates its kit for the analysis of KRAS and NRAS on the basis of the Amgen-AIFA information note

Diatech Pharmacogenetics updates its kit for the analysis of KRAS and NRAS on the basis of the Amgen-AIFA information note

We are pleased to inform you that the kit Myriapod® Colon status, recently placed on the market, allows the analysis using MassARRAY® 180 mutations in parallel in the 4 major oncogenes involved in the pathogenesis of colorectal cancer (KRAS, BRAF, PIK3CA, NRAS ). Among these mutations include those of codons 12, 13, 59, 61, 117, 146 of the RAS genes, which has been recognized a predictive value for the treatment of colorectal cancer with anti-EGFR monoclonal antibodies, as a result of the clinical studies PRIME and PEAK presented at the recent annual meeting of ASCO.

Likewise, the kit Anti-EGFR mAb response® (KRAS status) and Anti-EGFR mAb response® (NRAS status) for Pyrosequencing are being updated to give the possibility, already with the next batch of production, analyze all possible mutations present in codons 12, 13, 59, 61, 117, 146 KRAS and NRAS gene respectively.

—-
Registered names and trademarks mentioned in this document are to be considered protected by law, even when not expressly stated.

2017-08-23T12:55:50+00:00